With the promise of an agile and highly capable manufacturing platform, the pharmaceutical industry is adopting continuous manufacturing of drug products at an accelerated pace. The collaboration between industry, regulatory agencies and academia is delivering advancements in the technical understanding, infrastructure investments and regulatory framework needed to implement this emerging technology. Recent success stories on the approval of several drug products using continuous manufacturing proves that the approach is feasible and attractive for development of new drugs and for increasing efficiency in legacy products, while still meeting high quality standards. But uncertainty in the future of continuous manufacturing as a widely adopted technology still remains, with particular focus on the challenges to industry regarding technology investment, quality management risks, and the lack of global harmonization of regulatory requirements. In the plenary session, we will explore the vision of a pharmaceutical manufacturing sector that is highly capable of producing quality drug products through the implementation of advanced manufacturing approaches. We will also hear about the industry innovative thinking and strategic approaches that help drive decision-making on the adoption of new technology. Finally, the plenary will address the progress of industry-academic-regulatory consortia that can drive innovation through active research and development of the processes, equipment and people needed to address these challenges.